

**REPORT No. 33355-1/25/GDY/GDA/PK**

COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1

Sponsor		Sample according to declaration of Client
<b>NATU CARE SP. Z O.O</b> <b>OKOPOWA 58/72</b> <b>01-042 WARSZAWA</b> <b>POLAND</b>		<b>COLLAGEN PREMIUM 10000 MG,</b> <b>MANGO-PASSION FRUIT</b> <b>BATCH: 1</b> <b>PRODUCTION DATE: 30-11-2024</b> <b>EXPIRY DATE: 30-11-2026</b>
Sample reception date:	28.01.2025	Sample status: no objections Sample received from the Client
Start of the study:	03.02.2025	
End of the study	29.04.2025	
Report date:	09.05.2025	

**REPORT OF USE TEST AND INSTRUMENTAL TEST  
UNDER DERMATOLOGICAL CONTROL**

**CONTENT OF THE REPORT**

1.	INITIAL REPORT DESIGN.....	5
1.1	STUDY OBJECTIVES.....	5
1.2	ETHICAL CONDUCT OF THE STUDY.....	5
1.3	QUALITY CONTROL.....	6
1.4	RELEVANCE OF THE STUDY .....	6
1.5	ETHICAL COMMITTEE.....	6
1.6	INFORMATION OF THE TEST SUBJECT AND INFORMED CONSENT FORM.....	7
1.7	CONFIDENTIALITY OF THE SUBJECT .....	7
1.8	THE BASIS TO CONDUCT THE STUDY.....	8
2.	INVESTIGATIONAL PRODUCT.....	9
2.1	Description of the product .....	9
3.	STUDY DESCRIPTION.....	9
3.1	AIM OF THE STUDY.....	9
3.2	GENERAL PRINCIPLE OF THE STUDY .....	9
3.3	TESTING METHODOLOGY .....	10
3.3.1	Use test .....	10
3.3.2	Instrumental test .....	11
3.3.2.1	Instrumental test of skin moisturizing level by using Corneometer® CM 825 .....	11
3.3.2.2	Instrumental test of biomechanical skin parameters by using Cutometer® MPA 580 .....	11
3.3.2.3	Wrinkles analysis by using Antera 3D® .....	11
3.4	SUSPENSION OF THE STUDY .....	12
3.5	ADVERSE EVENTS .....	12
3.6	RAW DATA RECORDING .....	12
4.	DESCRIPTION OF SUBJECTS .....	14
5.	TRIAL SCHEDULE .....	16
6.	RESULTS .....	17
6.1	Characteristic of subjects .....	17
6.2	Assessment of the effect of the preparation on tolerance at the site of application on a group of subjects (repeated application).....	18
6.3	Confirmation of the effect claimed for the cosmetic product .....	20
6.4	The instrumental test results .....	21
6.4.1	Instrumental test of skin moisturizing level by using Corneometer® CM 825 .....	21
6.4.2	Instrumental test of biomechanical skin parameter by using Cutometer® MPA 580 .....	22
6.4.3	Instrumental test - analysis of wrinkles by using Antera 3D® .....	24
7.	CONCLUSION.....	35

8.	APPENDIX .....	37
8.1	Summary of the questionnaire .....	37
8.2	Answers to open questions .....	38
9.	SIGNATURES .....	40

**STUDY REFERENCE**

SPONSOR	<b>NATU CARE SP. Z O.O</b> OKOPOWA 58/72 01-042 WARSZAWA POLAND
STUDY MONITOR	Natalia Grajcar
INVESTIGATING CENTRE	<b>J.S. HAMILTON POLAND SP. Z O.O.</b> BAJANA 3D 80-463 GDAŃSK POLAND
PROJECT MANAGER	Marta Sadowska
DERMATOLOGIST	<b>Berenika Olszewska, MD, PhD</b> Registered N° 2880077
ETHICAL COMMITTEE APPROVAL	31.01.2025

**1. INITIAL REPORT DESIGN****1.1 STUDY OBJECTIVES**

The aim of the study was to check the tolerance and effectiveness of the investigational product **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1** on a panel of healthy human subjects after application under normal conditions of use.

**1.2 ETHICAL CONDUCT OF THE STUDY**

The described study was conducted in the spirit of the Good Clinical Practice defined by the ICH Topic E6 "Note for Guidance and good clinical practice" (CPMP/ICH/135/95), the Helsinki Declaration (1964, WMA) and its successive updates. The study was conducted according to Standard Operating Procedures and to the study protocol defined by the sponsor. All study events recorded during the study was reported. Controls on data veracity and conformity with the protocol was performed and confirmed by persons participating in the study.

**SCOPE OF TESTS COMPLIANT WITH:**

- Regulation of the European Parliament and of the Council (EC) No. 1223/2009 of 30 November 2009 on cosmetic products.
- Cosmetics Europe – The Personal Care Association (previously COLIPA) Guidelines "Product Test Guidelines for the Assessment of Human Skin Compatibility 1997."
- Cosmetics Europe – The Personal Care Association (previously COLIPA) Guidelines for the Evaluation of the Efficacy of Cosmetic Products 2008.
- Cosmetics Europe - The Personal Care Association (previously COLIPA) GUIDELINES FOR COSMETIC PRODUCT CLAIM SUBSTANTIATION Revising and expanding the Colipa Guidelines on Efficacy (2001/rev. 2008) 22 May 2019.

### **1.3 QUALITY CONTROL**

The study was performed in compliance with the procedures of the investigating centre, established according to the regulations in force.

The investigator, in charge of the performance of the study, made sure of the quality of the work of the technical staff, particularly concerning the respect of the protocol and its appendices, the collection of raw data, the management of the investigational product.

### **1.4 RELEVANCE OF THE STUDY**

Based on the existing data the purpose of the study was to determine the tolerance and effectiveness of the investigational product **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1**. This product will be used under normal conditions, the foreseeable risk incurred by the test subjects will be minor. So, there will be suitability between the aim of the study and its eventual risks and the foreseeable troubles related to the experimental conditions of the protocol.

The experimental conditions adopted for the tested formula **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1** (application area, quantity of investigational product applied, frequency of the applications...) was reproduced the normal conditions of use. The observance of the experimental conditions by the test subjects was assessed at the end of the study. The test subjects opinion was taken into account since it should reflect that of the potential consumers.

The skin examination was performed by the technician controlled by investigator having an appropriate experience.

### **1.5 ETHICAL COMMITTEE**

According to the procedure of investigating centre, the protocol, the informed consent form and the preclinical information concerning the investigational product **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1** was submitted to the internal committee of the investigating centre.

The committee got sure that the project meets the conditions of optimal scientific rigor, assessed its general relevance, the suitability between the aim followed and the means implemented and gave an opinion on the protection of the test subjects.

The study does not begin without the approval of the Survey committee.

**1.6 INFORMATION OF THE TEST SUBJECT AND INFORMED CONSENT FORM**

The information about the study was given orally and as a written document to each test subject before the start of the study. This information is accessible, understandable and suitable for each test subject. This information was completed, if necessary, by the investigator (or the competent person designated) who answered all the questions asked by the test subject.

The content of this document particularly specified:

- the aim of the study,
- the study design and the experimental conditions of the study,
- the approximate number of test subjects involved in the study,
- the expected duration of the study (for the test subject),
- the number of visits to the investigating centre, their dates and their duration,
- the study constraints (obligations, restrictions and troubles),
- that skin site photographs can be taken and in this case, that the test subject would not be recognizable,
- the opinion of the internal committee,
- the person to contact and the contact telephone number,
- that the personal data of the test subject would be confidentially treated by the study staff, available for the study monitor and possibly consulted (with the authorization of the test subject) by the auditors and the members of the internal committee,
- the ban on taking part simultaneously in other clinical studies,
- the amount of the compensation for the constraints to be undergone,
- the period of exclusion at the end of the study during which the test subject would not be allowed to take part in another clinical study,
- the confidential treatment of the study data,
- that the anonymity of the test subject was preserved,
- the freedom for the test subject to refuse to participate or to stop his participation at any time without any justification and any legal consequences.

At the beginning of the study, two copies of this document was dated and signed simultaneously by the test subject and by the investigator or the competent person designated. One copy was given to the test subject, the other was kept at the investigating center.

**1.7 CONFIDENTIALITY OF THE SUBJECT**

The information concerning the subject, required for his recruitment, inclusion and particularly that related to his health, obtained during the medical examination, formed part of medical secret and was confidentially treated.

The test subject was coded when included in the study to preserve his anonymity.

**1.8 THE BASIS TO CONDUCT THE STUDY**

- Samples delivered by the Sponsor.
- The qualitative composition of the product delivered by the Sponsor.
- The results of microbiological purity of the product provided by the Sponsor.
- Negative results of dermatological tests of the product provided by the Sponsor.

The Sponsor is responsible for conformity with the declared quality composition of the product, as well as microbiological purity test of the delivered samples.



## 2. INVESTIGATIONAL PRODUCT

### 2.1 Description of the product

Parameter	Description
Product reference	COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT BATCH: 1 PRODUCTION DATE: 30-11-2024 EXPIRY DATE: 30-11-2026
Intended use	The product is intended for supplementation.
Method of use	Dissolve one sachet twice a day in half a glass of water (lukewarm).

Contraindications for use of the product are: acute inflammation of the place of application, requiring pharmacological treatment, and allergy recognized or hypersensitivity to any of its ingredients.

The Sponsor is responsible for conformity of declared composition of the product with Regulation 1223/2009

## 3. STUDY DESCRIPTION

### 3.1 AIM OF THE STUDY

The aim of the study was to confirm/exclude of the declared product properties and to evaluate the direct influence of the investigational product **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1** on moisturizing skin level, improving biomechanical skin parameters and reduction of wrinkle following 86 consecutive days of use by a panel of 30 subjects.

### 3.2 GENERAL PRINCIPLE OF THE STUDY

The investigational product **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1** had to be applied, under normal conditions of use by the test subjects at home accordance with the declared method of use. The test subject was used as own control.

### 3.3 TESTING METHODOLOGY

#### 3.3.1 Use test

The use test conducted at home under dermatological control. The study concerned on:

- assess the impact of cosmetic on tolerance at the application site as a result of regular, repetitive application of the product, according to the purpose and use of the specified time (repetitive test);
  - ✓ the skin examination by technician before the product application and after regular use,
  - ✓ the analysis of the sensations of discomfort reported directly by the test subjects to the investigator, during the study or in the daily logs.

Based on the interview with the subject, the investigator assesses the physical signs before and after using product, using a 4-point scale from 0 to 3, and asks the subject about the functional signs:

		None (0)	Mild (1)	Moderate (2)	Severe (3)
<b>Physical signs</b>	<b>Redness/erythema</b>				
	<b>Swelling/oedema</b>				
	<b>Desquamation</b>				
	<b>Dryness</b>				
	<b>Pustules</b>				
	<b>Roughness</b>				
	<b>Other</b>				
If possible the subject reported the functional signs:					
		None (0)	Mild (1)	Moderate (2)	Severe (3)
<b>Functional signs</b>	<b>Warm/burning sensation</b>				
	<b>Itching/pruritus</b>				
	<b>Tightness</b>				
	<b>Stinging/prickling</b>				
	<b>Other</b>				

- research leading to confirm or exclude the properties claimed for the cosmetic.

The Evaluation Questionnaire form, the characteristics of the panel and number of subjects were in line with Sponsor requirements. The product was applied by subjects accordance with the declared method of use.

**Declarations will be confirmed only if the ratio of the received positive responses to the total number of subjects participating in the study will be above 50%**

**3.3.2 Instrumental test****3.3.2.1 Instrumental test of skin moisturizing level by using Corneometer® CM 825**

The aim of the test was to define the direct influence of the tested product on the skin moisture level. The test has been conducted using special measuring device manufactured by Courage + Khazaka Company – Corneometer® CM 825. Instrumental study has been carried out on 30 subjects. The measurements of moisturizing effect have been performed at the site of application – before product use (D0), after 42 days (D42) and after 86 days (D86) of regular use. The study has been carried out in an air conditioned room in the temp. of  $20\pm 2^{\circ}\text{C}$  and relative humidity  $50\pm 10\%$ . The product efficacy is confirmed in case of the positive results obtained in more than 50% of subjects.

**3.3.2.2 Instrumental test of biomechanical skin parameters by using Cutometer® MPA 580**

The aim of the test was to define the direct influence of the tested product on biomechanical skin parameter (firmness and elasticity) by using Cutometer® MPA 580. The test has been conducted using special measuring device manufactured by Courage + Khazaka Company. Instrumental study has been carried out on 30 subjects. The measurements have been performed at specified zone – before product use (D0), after 42 days (D42) and after 86 days (D86) of regular use. The study has been carried out in an air conditioned room in the temp. of  $20\pm 2^{\circ}\text{C}$  and relative humidity  $50\pm 10\%$ . The product efficacy is confirmed in case of the positive results obtained in more than 50% of subjects.

**3.3.2.3 Wrinkles analysis by using Antera 3D®**

The aim of the test was to define the direct influence of the tested product on reduction of wrinkle depth and width on the measurement zone by using Antera 3D®. The test has been conducted using special measuring device manufactured by Miravex Limited. Instrumental study has been carried out on 30 subjects. The measurements have been performed at specified zone – before product use (D0), after 42 days (D42) and after 86 days (D86) of regular use. The study has been carried out in an air conditioned room in the temp. of  $20\pm 2^{\circ}\text{C}$  and relative humidity  $50\pm 10\%$ . The product efficacy is confirmed in case of the positive results obtained in more than 50% of subjects.

### **3.4 SUSPENSION OF THE STUDY**

The investigator has to stop the study if it shows a risk for the health or the integrity of the test subjects. The date of the suspension and the reasons has to be carefully documented by the investigator in the case report form (CRF).

The investigating centre has to inform promptly the study monitor, by phone, fax or e-mail. The sponsor was able to stop the study at any time for administrative reasons or other ones.

### **3.5 ADVERSE EVENTS**

According to individual sensitivities, any product can induce a minor reactivity, defined as follows: any slight local reaction of intolerance or sensation of discomfort, occurring in a test subject during a clinical study, completely reversible, expected, due to the investigational product and which does not question the observance of the study protocol or the good implementation of the study.

- **adverse event:** any harmful event with or without relationship with the investigational product, occurring in a test subject during a clinical study.

- **serious adverse event:** any adverse event that causes death, endangers test subject's life, induces an hospitalization or the prolongation of the hospitalization, causes severe and lasting incapacity or handicap or induces congenital anomaly or malformation.

The investigator has to accurately describe the adverse event and has to appreciate its seriousness. According to the corresponding procedure of the investigating centre, he has to define the link of causality between this event and the investigational product, on the basis of the symptoms, the chronology, the results of the possible specific complementary tests undertaken and any available information.

The imputability of the investigational product has to be assessed according to the scale: very likely, likely, possible, questionable, excluded. In case of adverse effect (with a quite possible relationship with the investigational product), the investigator has to ensure the clinical follow-up of the test subject concerned, as long as necessary.

The serious adverse events has to be notified as soon as possible and within 24 hours at the latest, by the investigating centre to the study monitor, by phone, fax or e-mail. The investigator has to send an adverse event form to the study monitor.

### **3.6 RAW DATA RECORDING**

All the data gathered during the study was recorded accurately, legibly and indelibly by the investigator and the technician in charge of the study, under his control, in the case report form. This document was initialed by the technician or investigator.

At the end of the study, the information concerning the investigational product, the information concerning the test subjects (CRF(s), daily logs, informed consent forms) and the information related to the conduct of the study (protocol signed by the sponsor, copy of this study report....) were filed in the filing area of the investigating centre.

**4. DESCRIPTION OF SUBJECTS**

<b>GENERAL INCLUSION CRITERIA</b>	Healthy subject.	
	Sign an informed consent to participate in the study, were informed about the purpose of the study, the manner of its conduct and the possible side effects.	
	Skin without irritation and changes requiring pharmacological treatment.	
	Phototype: I – IV.	
	Cooperative subject, aware of the necessity and duration of controls.	
<b>SPECIFIC INCLUSION CRITERIA</b>	Amount of subjects:	30 subjects
	Gender:	Women
	Age:	30-60
	Skin type:	Dry and normal, sensitive and non-sensitive.
<b>NON INCLUSION CRITERIA</b>	The subject has any product applied to the tested zone.	
	A subject who has or has a known history of acute or chronic dermatological, medical and/or physical conditions that may affect the test result.	
	Pregnant or breastfeeding woman or woman planning a pregnancy during the study.	
	The subject shows allergic reactions to cosmetics, soaps or personal care products.	
	Subject abusing alcohol and/or drugs.	
	Subject undergoing treatment with sympathomimetics, antihistamines, nonsteroidal anti-inflammatory agents, corticosteroids and/or any other medications that could have interfered with the results of this study, within one week prior to initiation of this test.	
	Subject enrolled in another study during the study period.	
	Subject considered by the investigator to be likely not compliant to the protocol.	
<b>INFORMED CONSENT</b>	After an explanation of the protocol, reasons for the study, possible associated risks and potential benefits of the treatment each subject signed an informed consent form before starting the study.	

The qualified subjects received the tested product, specially developed questionnaire, the daily log and were obliged to:

- Regular use of the product according to the method of use,
- during the test any other products of similar effects must not be used,
- a detailed evaluation of the tested product by using the received questionnaire,
- in case of discomfort or any medicine taken fill the daily log,
- in case of any side effects on skin they should immediately stop using the product and consult investigator at J.S. Hamilton Poland.

Skin reactivity, history of atopy and contraception were documented by the investigator, in the case report form (CRF). No medication likely to interfere with the study was allowed during the study; however, if the health state of the subjects justifies some medication (particularly anti-inflammatory drugs), any information relating to this concomitant medication had to be carefully documented in the case report form. The investigator had to exclude the test subjects taking concomitant medication likely to interfere with the study and the interpretation of the results.

The test results may be affected by such factors as:

- the skin condition at the site of product application,
- inter-individual genetic characteristics,
- individual preferences of subjects.

**5. TRIAL SCHEDULE**

D0:

- The subjects came to the laboratory without having applied any product on the studied zone.
- Subjects signed consent informed form in duplicate.
- Verification of inclusion and non-inclusion criteria.
- The technician examined the study zone.
- The measurements of the studied zone:
  - Instrumental test of moisturizing level.
  - Instrumental test of biomechanical skin parameters.
  - Instrumental test of reduction of wrinkle.
- Distribution studied product, daily log and questionnaire. Each subject was instructed to use the tested product as described in daily log and record the dates of use.

D42:

- The subjects came to the laboratory without having applied any product on the studied zone.
- The technician examined the study zone.
- The measurements of the studied zone:
  - Instrumental test of moisturizing level.
  - Instrumental test of biomechanical skin parameters.
  - Instrumental test of reduction of wrinkle.
- Record of possible adverse reactions.

D86:

- The subjects came to the laboratory without having applied any product on the studied zone.
- The technician examined the study zone.
- The measurements of the studied zone:
  - Instrumental test of moisturizing level.
  - Instrumental test of biomechanical skin parameters.
  - Instrumental test of reduction of wrinkle.
- Collecting questionnaire.
- Record of possible adverse reactions.



**REPORT No. 33355-1/25/GDY/GDA/PK**

COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1

**6. RESULTS**
**6.1 Characteristic of subjects**

Subject's no.	Subject's code	Gender	Age	Facial skin type	Sensitive skin	Study initiation date (D0)		Study control date (D42)		Study completion date (D86)						
1.	TAR MI	W	37	N	N	3.02.2025		17.03.2025		28.04.2025						
2.	KED AN	W	56	D	N	3.02.2025		17.03.2025		28.04.2025						
3.	DOE SY	W	35	D	N	3.02.2025		17.03.2025		28.04.2025						
(4.)*	(SPR MA)*	(W)*	(34)*	(N)*	(N)*	3.02.2025		(The subject did not come to control study and did not finish the study.)*								
5.	SOB AN	W	48	N	N	3.02.2025		17.03.2025		30.04.2025						
6.	SZW AL	W	57	N	N	3.02.2025		17.03.2025		30.04.2025						
7.	CHM DO	W	39	D	N	3.02.2025		17.03.2025		28.04.2025						
8.	JAR AN	W	44	N	N	3.02.2025		17.03.2025		28.04.2025						
9.	KRA AL	W	44	N	N	3.02.2025		17.03.2025		28.04.2025						
10.	FRA DA	W	30	D	Y	3.02.2025		17.03.2025		28.04.2025						
11.	KOW BE	W	57	N	N	3.02.2025		17.03.2025		28.04.2025						
12.	HIG KA	W	55	D	N	3.02.2025		17.03.2025		28.04.2025						
13.	GAN BO	W	53	D	N	3.02.2025		17.03.2025		28.04.2025						
14.	JAW SY	W	46	N	N	3.02.2025		17.03.2025		28.04.2025						
15.	ZYD DO	W	32	N	Y	3.02.2025		17.03.2025		28.04.2025						
16.	ROD MA	W	48	N	N	4.02.2025		18.03.2025		29.04.2025						
17.	LES LU	W	38	N	N	4.02.2025		20.03.2025		29.04.2025						
18.	SKO HA	W	50	D	N	4.02.2025		18.03.2025		29.04.2025						
19.	DER BE	W	53	N	Y	4.02.2025		17.03.2025		(The subject did not finish the study.)						
20.	STO BE	W	50	D	N	4.02.2025		18.03.2025		29.04.2025						
21.	KAN MA	W	41	D	Y	4.02.2025		18.03.2025		29.04.2025						
22.	LAB KA	W	39	N	N	4.02.2025		18.03.2025		29.04.2025						
23.	LIP MA	W	60	D	N	4.02.2025		18.03.2025		29.04.2025						
24.	LUB IR	W	55	D	N	4.02.2025		18.03.2025		29.04.2025						
25.	BAL EL	W	60	D	N	4.02.2025		18.03.2025		29.04.2025						
26.	PIO KA	W	37	N	N	4.02.2025		18.03.2025		(The subject did not finish the study.)						
27.	SZC GR	W	58	D	N	4.02.2025		18.03.2025		29.04.2025						
28.	BRY MA	W	59	D	N	4.02.2025		18.03.2025		29.04.2025						
29.	RZE AL	W	55	D	Y	4.02.2025		18.03.2025		29.04.2025						
30.	TRZ MO	W	49	N	Y	6.02.2025		18.03.2025		29.04.2025						
		WOMEN (W)	29	MEAN	48	DRY (D)	15	YES (Y)	6	NUMBER OF SUBJECTS, WHO STARTED THE STUDY		30	NUMBER OF SUBJECTS, WHO CAME TO CONTROL STUDY	29	NUMBER OF SUBJECTS, WHO FINISHED THE STUDY	2
		MEN (M)	0	MIN	30	NORMAL (N)	14	NO (N)	23							
				MAX	60	COMBINATION (C)	0									
						OILY (O)	0									

Legend:

(\*)\* The subject was not included in the calculation

**REPORT No. 33355-1/25/GDY/GDA/PK**

COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1

**6.2 Assessment of the effect of the preparation on tolerance at the site of application on a group of subjects (repeated application)**

On the basis of interviews collected from subjects we found that the tested product **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1** was very well tolerated at the site of application. In all subjects, who finished the study, after regular use of the product, in the interview there was no negative symptoms or sensations that could indicate intolerance to any of the product ingredients, i.e. redness, burning, swelling, tingling sensations and itching, were observed or confirmed by interview. The product did not cause dryness at the site of application in any subjects.

**The results obtained in the test allow to conclude, that the product used as intended is very well tolerated by the people, in whom there is not a contraindication to its use.**

Table 2. Summary of the subject's evaluation

Subject's no.	Subjective Evaluations (D42) (as reported in daily logs)	Subjective Evaluations (D86) (as reported in daily logs)
1.	No reaction	No reaction
2.	No reaction	No reaction
3.	No reaction	No reaction
(4.)*	<i>(Untraceable)*</i>	
5.	No reaction	No reaction
6.	No reaction	No reaction
7.	No reaction	No reaction
8.	No reaction	No reaction
9.	No reaction	No reaction
10.	No reaction	No reaction
11.	No reaction	No reaction
12.	No reaction	No reaction
13.	No reaction	No reaction
14.	No reaction	No reaction
15.	No reaction	No reaction
16.	No reaction	No reaction
17.	No reaction	No reaction
18.	No reaction	No reaction
19.	No reaction	<i>(Untraceable)*</i>
20.	No reaction	No reaction
21.	No reaction	No reaction
22.	No reaction	No reaction
23.	No reaction	No reaction
24.	No reaction	No reaction
25.	No reaction	No reaction
26.	No reaction	<i>(Untraceable)*</i>
27.	No reaction	No reaction
28.	No reaction	No reaction
29.	No reaction	No reaction
30.	No reaction	No reaction

Legend:

(\*)\* The result was not included in the calculation.

**6.3 Confirmation of the effect claimed for the cosmetic product**

Based on the results of use test properties of product **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1** declared by the Client were assessed as follows:

The product visibly elasticizes and firms the skin.	89%	positive responses
The product makes the skin visibly less flabby.	85%	positive responses
The product makes the skin look younger.	89%	positive responses
The product improves the appearance of the skin.	89%	positive responses
The product leaves the skin visibly nourished.	93%	positive responses
The product evens out the skin tone.	81%	positive responses
The product visibly brightens the skin.	85%	positive responses
The product makes the skin smooth to the touch.	93%	positive responses
The product gives the skin a feeling of hydration.	93%	positive responses
The product visibly reduces wrinkles and fine lines.	78%	positive responses
The product reduces the visibility of wrinkles.	81%	positive responses
The product visibly reduces cellulite.	67%	positive responses
The product visibly lightens discolorations.	70%	positive responses
The product reduces the visibility of stretch marks on the body.	67%	positive responses
The product improves the condition of sagging skin.	89%	positive responses
The product visibly improves the condition of the skin around the eyes.	85%	positive responses
The product visibly improves the condition of nails.	89%	positive responses
The product reduces brittle nails.	89%	positive responses
The product improves the appearance of nails.	89%	positive responses
The product improves the appearance of hair.	96%	positive responses
The product visibly stimulates hair growth and seems to prevent hair loss.	96%	positive responses
The product makes hair stronger and shinier.	96%	positive responses
The product visibly increases hair density.	89%	positive responses
The first effects of using the preparation are visible after the first month - skin/hair/nails.	89%	positive responses

**Moreover:**

Suitable application.	93%	positive responses
Suitable taste.	96%	positive responses
Overall assessment of the product.	89%	positive responses
Comparing with other similar product used in the past, the tested product was assessed as better.	74%	positive responses
Intention of buying the product.	85%	positive responses
Willingness to recommend the product to a friend.	85%	positive responses

Answers on all questions are presented in the Appendix **8.1**.

Answers on open questions are presented in the Appendix **8.2**.

## 6.4 The instrumental test results

### 6.4.1 Instrumental test of skin moisturizing level by using Corneometer® CM 825

#### Assumption:

The product moisturizes the skin, when the parameter value increases.

Table 1. Corneometer® CM 825. The results obtained from measurements of skin moisture before product use (D0), after 42 days (D42) and after 86 days (D86) of regular use in a.u.

Subject's no.	Before (D0)	After 42 days (D42)	After 86 days (D86)	Difference (D42-D0)	Difference (D86-D0)
1.	40,6	41,6	43,3	1,0	2,6
2.	36,1	38,2	39,9	2,0	3,8
3.	29,7	31,5	33,9	1,9	4,2
(4.)*	(42,6)*	UN			
5.	49,7	49,8	50,2	0,0	0,5
6.	39,4	41,1	42,4	1,7	3,0
7.	34,9	35,8	36,8	0,9	1,9
8.	45,3	46,3	48,0	1,0	2,8
9.	40,1	41,0	42,1	0,9	2,1
10.	24,4	26,5	29,7	2,0	5,3
11.	38,0	38,7	39,6	0,7	1,6
12.	34,3	36,0	37,1	1,7	2,8
13.	32,8	34,4	37,2	1,7	4,4
14.	33,1	34,1	37,0	1,0	4,0
15.	44,7	45,0	45,5	0,3	0,7
16.	43,7	44,9	46,6	1,1	2,9
17.	41,1	41,7	42,1	0,6	1,0
18.	28,4	31,1	32,7	2,7	4,3
19.	41,8	42,0	UN	0,2	UN
20.	26,0	27,9	30,5	1,9	4,4
21.	30,5	31,5	33,8	1,0	3,3
22.	47,3	47,9	48,6	0,6	1,3
23.	22,9	25,3	28,6	2,4	5,7
24.	25,7	26,2	28,3	0,5	2,6
25.	22,0	23,3	25,0	1,4	3,1
26.	49,4	49,6	UN	0,2	UN
27.	31,9	32,5	33,0	0,6	1,1
28.	32,8	33,4	35,9	0,6	3,2
29.	24,0	27,0	30,2	3,0	6,2
30.	38,8	40,1	42,0	1,3	3,2
<b>Mean</b>	<b>35,5</b>	<b>36,7</b>	<b>37,8</b>	<b>1,2</b>	<b>3,0</b>
<b>Min</b>	<b>22,0</b>	<b>23,3</b>	<b>25,0</b>	<b>0,0</b>	<b>0,5</b>
<b>Max</b>	<b>49,7</b>	<b>49,8</b>	<b>50,2</b>	<b>3,0</b>	<b>6,2</b>
<b>SD</b>	<b>8,1</b>	<b>7,7</b>	<b>6,9</b>	<b>0,8</b>	<b>1,5</b>
<b>Median</b>	<b>34,9</b>	<b>36,0</b>	<b>37,1</b>	<b>1,0</b>	<b>3,0</b>
<b>Δ%</b>				<b>3%</b>	<b>9%</b>
<b>% subjects with positive effect</b>				<b>100%</b>	<b>100%</b>

#### Legend:

()\* - The result was not included in the calculation

UN - untraceable

**Conclusion:** The product **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1** moisturizes the skin after 42 days and 86 days of regular use.

### 6.4.2 Instrumental test of biomechanical skin parameter by using Cutometer® MPA 580

**Assumption:**

The product improves skin elasticity, when the parameter value increases.

The product improves skin firmness, when the parameter value decreases.

Table 2. Cutometer® MPA 580. The mean results of skin elasticity (R2 parameter) measurements before product use (D0), after 42 days (D42) and after 86 days (D86) of regular use.

Subject's no.	Before (D0)	After 42 days (D42)	After 86 days (D86)	Difference (D42-D0)	Difference (D86-D0)
1.	0,634	0,677	0,751	0,044	0,118
2.	0,589	0,696	0,738	0,107	0,149
3.	0,786	0,784	0,848	-0,002	0,062
(4.)*	(0,860)*	UN			
5.	0,772	0,807	0,891	0,035	0,119
6.	0,685	0,730	0,772	0,045	0,087
7.	0,694	0,775	0,766	0,081	0,072
8.	0,729	0,809	0,872	0,080	0,143
9.	0,704	0,721	0,790	0,017	0,085
10.	0,796	0,849	0,899	0,053	0,103
11.	0,603	0,634	0,669	0,031	0,066
12.	0,730	0,735	0,787	0,005	0,057
13.	0,719	0,749	0,799	0,030	0,080
14.	0,668	AV	0,837	AV	0,169
15.	0,751	0,696	0,765	-0,055	0,013
16.	0,669	AV	0,877	AV	0,208
17.	0,799	0,833	0,894	0,034	0,095
18.	0,641	0,767	0,834	0,126	0,193
19.	0,817	0,812	UN	-0,005	UN
20.	0,661	0,670	0,736	0,009	0,075
21.	0,694	0,716	0,764	0,021	0,069
22.	0,610	0,669	0,748	0,059	0,139
23.	0,697	0,725	0,778	0,028	0,081
24.	0,736	0,719	0,756	-0,017	0,020
25.	0,628	0,660	0,749	0,032	0,120
26.	0,853	0,870	UN	0,017	UN
27.	0,708	0,703	0,784	-0,004	0,077
28.	0,647	0,788	0,781	0,141	0,134
29.	0,720	0,742	0,843	0,022	0,123
30.	0,598	0,704	0,737	0,106	0,138
<b>Mean</b>	<b>0,701</b>	<b>0,742</b>	<b>0,795</b>	<b>0,038</b>	<b>0,104</b>
<b>Min</b>	<b>0,589</b>	<b>0,634</b>	<b>0,669</b>	<b>-0,055</b>	<b>0,013</b>
<b>Max</b>	<b>0,853</b>	<b>0,870</b>	<b>0,899</b>	<b>0,141</b>	<b>0,208</b>
<b>SD</b>	<b>0,069</b>	<b>0,061</b>	<b>0,058</b>	<b>0,045</b>	<b>0,047</b>
<b>Median</b>	<b>0,697</b>	<b>0,730</b>	<b>0,781</b>	<b>0,031</b>	<b>0,095</b>
<b>Δ%</b>				<b>5%</b>	<b>15%</b>
<b>% subjects with positive effect</b>				<b>81%</b>	<b>100%</b>

**Legend:**

(\*)\* - The result was not included in the calculation

AV – aberrant value

UN - untraceable

Table 3. Cutometer® MPA 580. The mean results of skin firmness (R0 parameter) measurements before product use (D0), after 42 days (D42) and after 86 days (D86) of regular use.

Subject's no.	Before (D0)	After 42 days (D42)	After 86 days (D86)	Difference (D42-D0)	Difference (D86-D0)
1.	0,283	0,268	0,281	-0,015	-0,002
2.	0,293	0,278	0,278	-0,015	-0,015
3.	0,302	0,222	0,238	-0,080	-0,064
(4.)*	(0,425)*	UN			
5.	0,327	0,301	0,292	-0,026	-0,035
6.	0,409	0,340	0,289	-0,069	-0,120
7.	0,382	0,376	0,360	-0,006	-0,022
8.	0,425	0,446	0,423	0,021	-0,002
9.	0,514	0,482	0,455	-0,032	-0,059
10.	0,311	0,258	0,248	-0,053	-0,062
11.	0,695	0,674	0,560	-0,022	-0,135
12.	0,283	0,257	0,249	-0,027	-0,034
13.	0,409	0,368	0,367	-0,040	-0,042
14.	0,506	AV	0,445	AV	-0,061
15.	0,382	0,315	0,288	-0,067	-0,093
16.	0,431	AV	0,258	AV	-0,173
17.	0,427	0,398	0,406	-0,029	-0,021
18.	0,428	0,224	0,214	-0,204	-0,214
19.	0,389	0,398	UN	0,008	UN
20.	0,618	0,476	0,426	-0,142	-0,192
21.	0,342	0,223	0,174	-0,119	-0,168
22.	0,324	0,346	0,338	0,022	0,014
23.	0,412	0,322	0,284	-0,090	-0,127
24.	0,284	0,187	0,208	-0,096	-0,076
25.	0,422	0,350	0,335	-0,072	-0,087
26.	0,500	0,396	UN	-0,104	UN
27.	0,310	0,279	0,273	-0,030	-0,037
28.	0,518	0,353	0,307	-0,165	-0,211
29.	0,375	0,243	0,229	-0,132	-0,146
30.	0,421	0,367	0,308	-0,055	-0,113
<b>Mean</b>	<b>0,404</b>	<b>0,339</b>	<b>0,316</b>	<b>-0,061</b>	<b>-0,085</b>
<b>Min</b>	<b>0,283</b>	<b>0,187</b>	<b>0,174</b>	<b>-0,204</b>	<b>-0,214</b>
<b>Max</b>	<b>0,695</b>	<b>0,674</b>	<b>0,560</b>	<b>0,022</b>	<b>0,014</b>
<b>SD</b>	<b>0,100</b>	<b>0,103</b>	<b>0,090</b>	<b>0,057</b>	<b>0,067</b>
<b>Median</b>	<b>0,409</b>	<b>0,340</b>	<b>0,289</b>	<b>-0,053</b>	<b>-0,064</b>
<b>Δ%</b>				<b>-15%</b>	<b>-21%</b>
<b>% subjects with positive effect</b>				<b>89%</b>	<b>96%</b>

Legend:

(\*) - The result was not included in the calculation

AV – aberrant value

UN - untraceable

**Conclusion:** The product **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1** improves skin elasticity and skin firmness after 42 days and 86 days of regular use.

**6.4.3 Instrumental test - analysis of wrinkles by using Antera 3D®**
Assumption:

The product reduces wrinkles depth and width, when the parameters value decrease.

Table 4. Antera 3D®. The results of wrinkles depth measurement before product application (D0), after 42 days (D42) and after 84 days (D84) of regular use in mm.

Subject's no.	Before (D0)	After 42 days (D42)	After 84 days (D84)	Difference (D42-D0)	Difference (D84-D0)
1.	0,029	0,020	0,023	-0,008	-0,006
2.	0,051	0,021	0,043	-0,030	-0,008
3.	0,043	0,038	0,024	-0,005	-0,019
(4.)*	(0,046)*	UN			
5.	0,042	0,030	0,026	-0,012	-0,016
6.	0,032	0,031	0,031	-0,001	-0,001
7.	0,082	0,072	0,069	-0,010	-0,014
8.	0,048	0,033	0,040	-0,015	-0,008
9.	0,069	0,068	0,068	-0,001	-0,002
10.	0,019	0,021	0,019	0,002	0,000
11.	0,038	0,032	0,037	-0,006	-0,001
12.	0,041	0,022	0,040	-0,019	-0,001
13.	0,076	0,051	0,043	-0,025	-0,033
14.	0,026	0,023	0,027	-0,003	0,001
15.	0,034	0,030	0,024	-0,004	-0,010
16.	0,029	0,029	0,022	0,000	-0,007
17.	0,045	0,032	0,031	-0,012	-0,014
18.	0,062	0,056	0,048	-0,006	-0,014
19.	0,038	0,035	UN	-0,003	UN
20.	0,033	0,030	0,029	-0,003	-0,004
21.	0,034	0,020	0,022	-0,014	-0,012
22.	0,066	0,065	0,063	0,000	-0,003
23.	0,027	0,022	0,025	-0,005	-0,001
24.	0,078	0,067	0,050	-0,011	-0,028
25.	0,066	0,057	0,042	-0,009	-0,024
26.	0,031	0,027	UN	-0,004	UN
27.	0,029	0,021	0,020	-0,008	-0,009
28.	0,036	0,024	0,029	-0,011	-0,006
29.	0,075	0,072	0,071	-0,004	-0,004
30.	0,039	0,027	0,027	-0,012	-0,012
<b>Mean</b>	<b>0,045</b>	<b>0,037</b>	<b>0,037</b>	<b>-0,008</b>	<b>-0,009</b>
<b>Min</b>	<b>0,019</b>	<b>0,020</b>	<b>0,019</b>	<b>-0,030</b>	<b>-0,033</b>
<b>Max</b>	<b>0,082</b>	<b>0,072</b>	<b>0,071</b>	<b>0,002</b>	<b>0,001</b>
<b>SD</b>	<b>0,018</b>	<b>0,018</b>	<b>0,016</b>	<b>0,007</b>	<b>0,009</b>
<b>Median</b>	<b>0,039</b>	<b>0,030</b>	<b>0,031</b>	<b>-0,006</b>	<b>-0,008</b>
<b>Δ%</b>				<b>-18%</b>	<b>-20%</b>
<b>% subjects with positive effect</b>				<b>97%</b>	<b>93%</b>

## Legend:

()\* - The result was not included in the calculation

UN - untraceable



Table 5. Antera 3D®. The results of wrinkles width measurement before product application (D0), after 42 days (D42) and after 84 days (D84) of regular use in mm.

Subject's no.	Before (D0)	After 42 days (D42)	After 84 days (D84)	Difference (D42-D0)	Difference (D84-D0)
1.	1,196	1,250	1,216	0,054	0,020
2.	1,293	1,263	1,223	-0,030	-0,070
3.	1,270	1,251	1,228	-0,019	-0,042
(4.)*	(1,336)*	UN			
5.	1,317	1,292	1,140	-0,025	-0,177
6.	1,259	0,997	1,136	-0,262	-0,123
7.	1,385	1,310	1,200	-0,075	-0,185
8.	1,386	1,263	1,260	-0,123	-0,126
9.	1,443	1,379	1,458	-0,064	0,015
10.	1,228	1,217	1,123	-0,011	-0,105
11.	1,280	1,216	1,181	-0,064	-0,099
12.	1,251	1,241	1,244	-0,010	-0,007
13.	1,317	1,232	1,265	-0,085	-0,052
14.	1,345	1,309	1,251	-0,036	-0,094
15.	1,273	1,209	1,127	-0,064	-0,146
16.	1,382	1,140	1,273	-0,242	-0,109
17.	1,316	1,275	1,321	-0,041	0,005
18.	1,243	1,319	1,318	0,076	0,075
19.	1,416	1,393	UN	-0,023	UN
20.	1,227	1,224	1,268	-0,003	0,041
21.	1,155	1,042	1,119	-0,113	-0,036
22.	1,351	1,346	1,318	-0,005	-0,033
23.	1,311	1,158	1,154	-0,153	-0,157
24.	1,288	1,190	1,119	-0,098	-0,169
25.	1,303	1,248	1,225	-0,055	-0,078
26.	1,259	1,239	UN	-0,020	UN
27.	1,291	1,237	1,245	-0,054	-0,046
28.	1,200	1,156	1,135	-0,044	-0,065
29.	1,412	1,245	1,143	-0,167	-0,269
30.	1,297	1,256	1,242	-0,041	-0,055
<b>Mean</b>	<b>1,300</b>	<b>1,238</b>	<b>1,220</b>	<b>-0,062</b>	<b>-0,077</b>
<b>Min</b>	<b>1,155</b>	<b>0,997</b>	<b>1,119</b>	<b>-0,262</b>	<b>-0,269</b>
<b>Max</b>	<b>1,443</b>	<b>1,393</b>	<b>1,458</b>	<b>0,076</b>	<b>0,075</b>
<b>SD</b>	<b>0,070</b>	<b>0,085</b>	<b>0,081</b>	<b>0,074</b>	<b>0,078</b>
<b>Median</b>	<b>1,293</b>	<b>1,245</b>	<b>1,225</b>	<b>-0,044</b>	<b>-0,070</b>
<b>Δ%</b>				<b>-5%</b>	<b>-6%</b>
<b>% subjects with positive effect</b>				<b>93%</b>	<b>81%</b>

Legend:


()\* - The result was not included in the calculation

UN - untraceable

**REPORT No. 33355-1/25/GDY/GDA/PK**


COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1

Table 6. Visual presentation of results showing the site of application before product application (D0), after 42 days (D42) and after 84 days (D84) of regular use.



**REPORT No. 33355-1/25/GDY/GDA/PK**


COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1






**REPORT No. 33355-1/25/GDY/GDA/PK**

COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1




**REPORT No. 33355-1/25/GDY/GDA/PK**

COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1



**REPORT No. 33355-1/25/GDY/GDA/PK**


COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1






**REPORT No. 33355-1/25/GDY/GDA/PK**

COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1



**REPORT No. 33355-1/25/GDY/GDA/PK**


COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1






**REPORT No. 33355-1/25/GDY/GDA/PK**

COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1





Conclusion: The product **COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1** reduces wrinkles depth and wrinkles width after 42 days and 86 days of regular use.

**7. CONCLUSION**

Under these study conditions, after 86 days of regular use it is concluded, that the product

**COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1:**

- was tested under dermatological control,
- was tested by 30 subjects,
- was used once a day,
- was very well tolerated at the application site,
- properties declared by the Client have been confirmed basing on a subjective questionnaire:
  - The product visibly elasticizes and firms the skin.
  - The product makes the skin visibly less flabby.
  - The product makes the skin look younger.
  - The product improves the appearance of the skin.
  - The product leaves the skin visibly nourished.
  - The product evens out the skin tone.
  - The product visibly brightens the skin.
  - The product makes the skin smooth to the touch.
  - The product gives the skin a feeling of hydration.
  - The product visibly reduces wrinkles and fine lines.
  - The product reduces the visibility of wrinkles.
  - The product visibly reduces cellulite.
  - The product visibly lightens discolorations.
  - The product reduces the visibility of stretch marks on the body.
  - The product improves the condition of sagging skin.
  - The product visibly improves the condition of the skin around the eyes.
  - The product visibly improves the condition of nails.
  - The product reduces brittle nails.
  - The product improves the appearance of nails.
  - The product improves the appearance of hair.
  - The product visibly stimulates hair growth and seems to prevent hair loss.
  - The product makes hair stronger and shinier.
  - The product visibly increases hair density.
  - The first effects of using the preparation are visible after the first month - skin/hair/nails.
- based declared by the Client have been confirmed basing on instrumental tests:
  - ✓ after 42 days of regular use:
    - moisturizes the skin (average 3%),

**REPORT No. 33355-1/25/GDY/GDA/PK**

COLLAGEN PREMIUM 10000 MG, MANGO-PASSION FRUIT, BATCH:1

- improves skin elasticity (average 5%) and firmness (average 15%),
  - reduces wrinkles depth (average 18%) and wrinkles width (average 5%);
- ✓ after 86 days of regular use:
- moisturizes the skin (average 9%),
  - improves skin elasticity (average 15%) and firmness (average 21%),
  - reduces wrinkles depth (average 20%) and wrinkles width (average 6%).

## 8. APPENDIX

### 8.1 Summary of the questionnaire

One subject presents 3,7%. Values are rounded off.

33355-1/25/GDY/GDA/PK							
I. ASSESSMENT OF THE PRODUCT'S PROPERTIES							
	DEFINITELY NOT SUITABLE	NOT SUITABLE	SUITABLE	DEFINITELY SUITABLE			
1	Product application.	4%	4%	41%			52%
2	Product taste.	0%	4%	41%			56%
II. ASSESSMENT OF THE PRODUCT PROPERTIES							
	Definitely no	No	Yes	Definitely yes			
3	The product visibly elasticizes and firms the skin.	0%	11%	67%			22%
4	The product makes the skin visibly less flabby.	0%	15%	63%			22%
5	The product makes the skin look younger.	0%	11%	67%			22%
6	The product improves the appearance of the skin.	0%	11%	67%			22%
7	The product leaves the skin visibly nourished.	0%	7%	70%			22%
8	The product evens out the skin tone.	0%	19%	59%			22%
9	The product visibly brightens the skin.	0%	15%	63%			22%
10	The product makes the skin smooth to the touch.	0%	7%	70%			22%
11	The product gives the skin a feeling of hydration.	0%	7%	74%			19%
12	The product visibly reduces wrinkles and fine lines.	0%	22%	59%			19%
13	The product reduces the visibility of wrinkles.	0%	19%	63%			19%
14	The product visibly reduces cellulite.	4%	30%	52%			15%
15	The product visibly lightens discolorations.	0%	30%	56%			15%
16	The product reduces the visibility of stretch marks on the body.	4%	30%	52%			15%
17	The product improves the condition of sagging skin.	0%	11%	67%			22%
18	The product visibly improves the condition of the skin around the eyes.	0%	15%	63%			22%
19	The product visibly improves the condition of nails.	0%	11%	59%			30%
20	The product reduces brittle nails.	0%	11%	59%			30%
21	The product improves the appearance of nails.	4%	7%	59%			30%
22	The product improves the appearance of hair.	0%	4%	70%			26%
23	The product visibly stimulates hair growth and seems to prevent hair loss.	0%	4%	63%			33%
24	The product makes hair stronger and shinier.	0%	4%	67%			30%
25	The product visibly increases hair density.	0%	11%	59%			30%
26	The first effects of using the preparation are visible after the first month - skin/hair/nails.	4%	7%	59%			30%
27	What did you particularly like about the product?	...					
28	What did not you like about the product?	...					
III. MARKETING ASSESSMENT AFTER 28 DAYS OF REGULAR USE							
	Definitely I do not like it	I do not like it	Neutral	I like it	I definitely like it	No comparison	
29	Overall assessment of the product.	0%	0%	11%	41%		48%
	Definitely worse	Worse	Comparable	Better	Definitely better		
30	Product assessment in comparison with the same type of products used before.	0%	4%	7%	26%	48%	15%
	I definitely would not buy it	I would not buy it	I do not know whether I would buy it or not	I would buy it	I definitely would buy it		
31	Taking under consideration previously tested properties of the products, what is the probability that you will buy this product?	0%	4%	11%	33%		52%
	I would definitely not recommend it	I would not recommend it	I do not know whether I would recommend it or not	I would recommend it	I would definitely recommend it		
32	Would you recommend this product to a friend?	0%	0%	15%	33%	52%	



**8.2 Answers to open questions**

Subject's no.	What did you particularly like about the product?
1.	Very good effect on my brittle nails.
2.	Nice taste and smell, easy to apply.
3.	I noticed that my hair grows faster.
(4.)*	(Untraceable)*
5.	Results on the skin, taste.
6.	Good taste, effectively improves the condition of the skin, hair and nails.
7.	Taste
8.	Hair improvement.
9.	It is convenient to use.
10.	Taste
11.	Effect on nails.
12.	Taste
13.	Taste
14.	Taste, consistency, color.
15.	Taste of sachets, no fishy taste, easy to open sachets.
16.	Taste
17.	Taste
18.	Taste
(19.)*	(Untraceable)*
20.	Easy to apply and tastes divine.
21.	That works for the above mentioned questions :)
22.	I am delighted with the product and its effectiveness, nice taste.
23.	Taste
24.	Easy to use and quick to prepare.
25.	Taste
(26.)*	(Untraceable)*
27.	Taste
28.	Taste, smell, packaging, dissolves well.
29.	Taste and effect.
30.	None

Legend:




()\* - The result was not included in the calculation

Question no. 28	
Subject's no.	What did not you like about the product?
1.	It is difficult to dissolve in water.
2.	None
3.	None
(4.)*	(Untraceable)*
5.	None
6.	I like everything
7.	Smell
8.	It is difficult to dissolve in water.
9.	None
10.	None
11.	None
12.	Too short, please give me another 3 months.
13.	None
14.	None
15.	There are no big wow effects 😊 except for the hair which falls out less and there is a bit more of it.
16.	None
17.	The smell of fish
18.	None
(19.)*	(Untraceable)*
20.	None
21.	None
22.	None
23.	None
24.	None
25.	None
(26.)*	(Untraceable)*
27.	I like everything
28.	None
29.	None
30.	None

Legend:

()\* - The result was not included in the calculation

**9. SIGNATURES**

Project Manager:	Sign and date  09.05.2025
Quality Assurance Auditor:	Sign and date  09.05.2025
Dermatologist:	Sign and date  09.05.2025 No. PWZ 2880077

Laboratory: ul. Bajana 3D, 80-463 Gdańsk, Poland

The results relate to the analysed samples only.

This Report cannot be reproduced partially without a prior written consent of J.S. Hamilton Poland Sp. z o.o. Responsibility of J.S. Hamilton Poland Sp. z o.o. is restricted exclusively to the results and statements presented in original copy of the Report. The service confirmed by this Report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on [www.hamilton.com.pl](http://www.hamilton.com.pl)

---

**END OF THE REPORT**